NCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04027647 2025-06-12
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04946968 2025-06-11
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04811001 2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT01520870 2021-07-06
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT01728233 2021-05-14
HER-Uro01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT04675008 2021-01-05
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
Phase 2 Unknown
NCT04339829 2020-04-09
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT01112527 2018-08-16
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT02047747 2016-09-22
A Phase II Study of Dacomitinib in Progressive Brain Metastases
University of California, San Diego
Phase 2 Terminated
NCT01152853 2015-11-20
PF299804-AGC
Seoul National University Hospital
Phase 2 Completed
NCT01449201 2014-09-30
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Yonsei University
Phase 2 Completed